A research agenda for moving early medical pregnancy termination over the counter

Given the overall safety profile and increasing availability of medical pregnancy termination drugs, we asked: would the mifepristone–misoprostol regimen for medical termination at ≤10 weeks of gestation meet US Food and Drug Administration regulatory criteria for over‐the‐counter (OTC) approval, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapp, N, Grossman, D, Jackson, E, Castleman, L, Brahmi, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637897/
https://www.ncbi.nlm.nih.gov/pubmed/28317327
http://dx.doi.org/10.1111/1471-0528.14646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637897/
https://www.ncbi.nlm.nih.gov/pubmed/28317327
http://dx.doi.org/10.1111/1471-0528.14646

Ejemplares similares